Contact, Site Public |
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy |
|
|
| Active, not recruiting | 1 | 16 | Europe, Japan, US, RoW | Mezagitamab, TAK-079 | Takeda | Kidney Disease, Glomerulonephritis | 03/26 | 03/26 | | |
NCT04506619 / 2020-002726-84: Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants |
|
|
| Terminated | N/A | 26 | Europe, US | No Intervention | Oak Hill Bio Ltd | Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity | 08/22 | 08/22 | | |
| Completed | N/A | 179 | Europe, Canada, RoW | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 02/23 | 02/23 | | |
INTUITION-CPF, NCT04844593: A Study Using Artificial Intelligence to Identify Adults With Complex Perianal Fistulas Associated With Crohn's Disease |
|
|
| Completed | N/A | 32 | Europe | | Takeda | Crohn Disease, Rectal Fistula | 02/23 | 04/24 | | |
NCT05795361: Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome |
|
|
| Available | N/A | | Europe, US, RoW | Idursulfase-IT, HGT-2310, TAK-609 | Takeda | Hunter Syndrome | | | | |
NCT05265078: A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi |
|
|
| Completed | N/A | 102 | Europe | | Takeda | Von Willebrand Disease (VWD) | 04/23 | 04/23 | | |
DOrianT, NCT04659798: A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice |
|
|
| Completed | N/A | 240 | Europe | | Takeda | Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis | 04/23 | 08/23 | | |
NCT04877431: A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease |
|
|
| Completed | N/A | 45 | RoW | | Takeda | Short Bowel Syndrome | 06/23 | 06/23 | | |
NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults |
|
|
| No Longer Available | N/A | | Europe, Canada, US | Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg | Shire, Takeda Development Center Americas, Inc. | Hereditary Angioedema (HAE), Angioedema | | | | |
| Completed | N/A | 48 | RoW | | Takeda | Angioedemas, Hereditary | 08/23 | 08/23 | | |
ermEX-20, NCT05419700: A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion |
|
|
| Completed | N/A | 76 | Europe | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 09/23 | 09/23 | | |
NCT05695560: A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers |
|
|
| Completed | N/A | 12 | Canada | No Intervention | Takeda | Von Willebrand Disease (VWD) | 11/23 | 11/23 | | |
| Active, not recruiting | N/A | 2800 | RoW | | Takeda | Lymphoma | 12/24 | 12/24 | | |
NCT05489640: A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home |
|
|
| Recruiting | N/A | 100 | Europe | No Intervention | Takeda | Hereditary Angioedema (HAE) | 06/24 | 06/24 | | |
PROSPECT, NCT05578417: A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada |
|
|
| Recruiting | N/A | 150 | Canada | No Intervention | Takeda | Hereditary Angioedema (HAE), Angioedema | 03/24 | 06/24 | | |
NCT03824522: Post Marketing Surveillance Study for ADYNOVATE in South Korea |
|
|
| Completed | N/A | 341 | RoW | ADYNOVATE, PEGylated rFVIII | Takeda, Takeda Pharma Korea Co. Ltd. | Hemophilia A | 01/24 | 01/24 | | |
NCT04885920: A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA) |
|
|
| Completed | N/A | 120 | Europe, RoW | | Takeda | Inflammatory Bowel Diseases, Crohns Disease, Colitis, Ulcerative | 03/24 | 03/24 | | |
| Recruiting | N/A | 1000 | RoW | | Takeda | Lymphoma | 06/24 | 06/24 | | |
NCT05371028: A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada |
|
|
| Recruiting | N/A | 100 | Canada | Non-interventional Study | Takeda | Short Bowel Syndrome (SBS) | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 50 | Europe | No intervention | Takeda | Fabry Disease | 04/24 | 04/24 | | |
| Recruiting | N/A | 3000 | RoW | No Intervention | Jeil Pharmaceutical Co., Ltd. | Constipation | 05/24 | 11/24 | | |
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice |
|
|
| Active, not recruiting | N/A | 500 | RoW | | Takeda | Colitis, Ulcerative, Crohn Disease | 07/24 | 07/24 | | |
DRALEGA, NCT05982717: A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain |
|
|
| Recruiting | N/A | 250 | Europe | No intervention | Takeda | Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | 05/24 | 05/24 | | |
NCT04840680: A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM) |
|
|
| Recruiting | N/A | 165 | RoW | No Intervention | Takeda | Multiple Myeloma | 06/24 | 06/24 | | |
NCT05886478: A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin |
|
|
| Recruiting | N/A | 50 | Europe | No intervention | Takeda | T-Cell Lymphoma | 06/24 | 06/24 | | |
| Withdrawn | N/A | 30 | Europe | No Intervention | Takeda | Metachromatic Leukodystrophy (MLD) | 07/24 | 07/24 | | |
NCT06346899: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China |
|
|
| Not yet recruiting | N/A | 130 | RoW | No intervention | Takeda | Hereditary Angioedema (HAE) | 08/25 | 08/25 | | |
ENABLE, NCT04130191: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II |
|
|
| Active, not recruiting | N/A | 140 | Europe, RoW | | Shire, Takeda Development Center Americas, Inc. | Hereditary Angioedema (HAE) | 09/24 | 09/24 | | |
LANDSCAPE, NCT04943796: A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life |
|
|
| Recruiting | N/A | 576 | Europe, Canada | | Takeda | Attention Deficit Hyperactivity Disorder (ADHD) | 09/24 | 09/24 | | |
| Recruiting | N/A | 3000 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
NCT06104878: A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone |
|
|
| Withdrawn | N/A | 200 | RoW | No Intervention | Takeda | Hodgkin Lymphoma | 10/24 | 10/24 | | |
ELEGANT, NCT05737849: A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China |
|
|
| Withdrawn | N/A | 10800 | RoW | No Intervention | Takeda | Non-small Cell Lung Cancer (NSCLC) | 12/24 | 12/24 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 01/25 | 01/25 | | |
| Active, not recruiting | N/A | 72 | Europe, Canada, RoW | No Intervention | Takeda | Crohn's Disease | 01/25 | 01/25 | | |
PEDS, NCT04721366: A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease |
|
|
| Completed | N/A | 11 | US | Standard of Care, SOC | Takeda | Gaucher Disease | 04/23 | 04/23 | | |
NCT05626088: A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil |
|
|
| Recruiting | N/A | 2160 | RoW | No Intervention | Takeda | Ulcerative Colitis, Crohn's Disease | 01/25 | 01/25 | | |
HyMMy, NCT05879757: Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency |
|
|
| Recruiting | N/A | 100 | Europe, RoW | No Intervention | Takeda | Multiple Myeloma, Secondary Immunodeficiency (SID) | 07/25 | 03/26 | | |
| Recruiting | N/A | 111 | RoW | | Takeda | Multiple Myeloma | 08/25 | 08/25 | | |
VARIETY, NCT05384080: A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland |
|
|
| Active, not recruiting | N/A | 165 | Europe | | Takeda | Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis | 08/25 | 08/25 | | |
NCT05013190: A Study of NINLARO® in Chinese Adults With Multiple Myeloma |
|
|
| Recruiting | N/A | 320 | RoW | No intervention | Takeda | Multiple Myeloma | 10/25 | 10/25 | | |
NCT04961840: A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy |
|
|
| Active, not recruiting | N/A | 100 | US | No Intervention | Takeda | Constipation, Pregnancy | 12/25 | 12/25 | | |
NCT04799496: A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis |
|
|
| Recruiting | N/A | 600 | RoW | | Takeda | Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease | 01/26 | 01/26 | | |
| Recruiting | N/A | 40 | Europe | | Takeda | Hereditary Angioedema (HAE) | 03/26 | 03/26 | | |
NCT04869280: Post-Marketing Study of Prucalopride Safety In Pregnancy |
|
|
| Recruiting | N/A | 616 | US | No Intervention | Takeda, The Organization of Teratology Information Specialists | Chronic Idiopathic Constipation (CIC) | 05/26 | 05/26 | | |
| Recruiting | N/A | 70 | Europe | No Intervention | Takeda | Hodgkin Lymphoma | 06/26 | 06/26 | | |
NCT04838522: A Study of Prucalopride in Breastfeeding Women With Constipation |
|
|
| Recruiting | N/A | 12 | US | No Intervention | Takeda, UC San Diego Human Milk Research Biorepository | Chronic Idiopathic Constipation (CIC) | 12/26 | 12/26 | | |
NCT01034969: Firazyr® Patient Registry (Icatibant Outcome Survey - IOS) |
|
|
| Recruiting | N/A | 3000 | Europe, RoW | | Shire, Takeda Development Center Americas, Inc. | Hereditary Angioedema (HAE) | 01/27 | 01/27 | | |
ENTIRETY, NCT05735327: A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | N/A | 50 | Europe | No intervention | Takeda | Non-small Cell Lung Cancer (NSCLC) | 06/27 | 06/27 | | |
NCT05428345: A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea |
|
|
| Recruiting | N/A | 600 | RoW | | Takeda | Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease (IBD) | 11/27 | 11/27 | | |
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A |
|
|
| Active, not recruiting | N/A | 207 | Europe, US, RoW | ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855 | Baxalta now part of Shire | Hemophilia A | 02/30 | 02/30 | | |
| Active, not recruiting | N/A | 1340 | Europe, Canada, US | No intervention | Takeda, Takeda Development Center Americas, Inc. | Hypoparathyroidism | 11/34 | 11/34 | | |
Green, China |
| Recruiting | N/A | 6500 | Europe, Canada, US | AtriClip LAA Exclusion System | AtriCure, Inc., Population Health Research Institute | Ischemic Stroke, Systemic Embolism | 12/31 | 04/32 | | |
Wilson, Nathan |
NCT04901806: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors |
|
|
| Terminated | 1 | 29 | Europe, US, RoW | PBI-200 | Pyramid Biosciences | Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor | 07/23 | 07/23 | | |
Jackson, Jonathan L |
| Recruiting | 2 | 45 | US | Pembrolizumab, KEYTRUDA®, MK-3475, Olaparib, AZD-2281, MK-7339, KU0059436, Cisplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-platinum, IMRT (intensity modulated radiation therapy) | UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC | Squamous Cell Carcinoma of Head and Neck | 10/25 | 10/26 | | |
Orr, Brian |
| Terminated | 3 | 20 | Canada, US, RoW | Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo | Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT) | High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 09/23 | 09/23 | | |
| Terminated | 1/2 | 52 | Europe, US, RoW | NM21-1480 | Numab Therapeutics AG | Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer | 02/24 | 02/24 | | |
NCT05483933: Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers |
|
|
| Active, not recruiting | 1 | 86 | Europe, Canada, US | Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV | Shattuck Labs, Inc. | Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma | 07/24 | 04/25 | | |
Bickford, Megan |
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders |
|
|
| Completed | 2 | 257 | US | Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent | National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc. | Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS) | 06/23 | 03/24 | | |
Overstreet, Morgan |
| Completed | N/A | 140 | Canada, US | DrugSorb-ATR system, Sorbent hemoperfusion system, Sham comparator | CytoSorbents, Inc | Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative | 08/23 | 08/23 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 06/24 | 06/28 | | |
NCT05614869: Continuous Treatment With PREVENA Therapy for 14 Days |
|
|
| Recruiting | N/A | 353 | US | Prevena Plus Incision Management System with Prevena Dressings | 3M | Abdominal Surgery, Orthopedic Surgery, Cardiovascular Surgery, Vascular Surgery | 03/27 | 05/27 | | |
ROADSTER 3, NCT05365490: Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease |
|
|
| Recruiting | N/A | 400 | US | Transcarotid Artery Revascularization (TCAR), Carotid Revascularization, Carotid Artery Stenting | Silk Road Medical | Carotid Artery Diseases | 05/25 | 05/25 | | |
| Recruiting | N/A | 5000 | US | OCS Heart | TransMedics | Heart Transplant | 08/29 | 08/33 | | |
Lodha, Ankur |
| Recruiting | N/A | 75 | US | Misago® RX Self-expanding Peripheral Stent | Terumo Medical Corporation | Iliac Artery Stenosis | 06/24 | 12/26 | | |
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial |
|
|
| Active, not recruiting | N/A | 2005 | US | Orbital Atherectomy, Balloon | Abbott Medical Devices, Cardiovascular Research Foundation, New York | Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction | 06/24 | 06/25 | | |
DEEPER REVEAL, NCT05358353: A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee |
|
|
| Recruiting | N/A | 130 | US | Bare Temporary Spur Stent System | ReFlow Medical, Inc. | Peripheral Arterial Disease, Critical Limb Ischemia | 10/24 | 10/24 | | |
Kaczmar, John |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
VERSATILE002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC |
|
|
| Active, not recruiting | 2 | 95 | Europe, US | Pembrolizumab (KEYTRUDA®) and PDS0101 | PDS Biotechnology Corp., Merck Sharp & Dohme LLC | Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck | 06/25 | 06/25 | | |
|
| Recruiting | 2 | 45 | US | Pembrolizumab, KEYTRUDA®, MK-3475, Olaparib, AZD-2281, MK-7339, KU0059436, Cisplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-platinum, IMRT (intensity modulated radiation therapy) | UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC | Squamous Cell Carcinoma of Head and Neck | 10/25 | 10/26 | | |
| Recruiting | 2 | 340 | Europe, US | RP1, nivolumab, Opdivo | Replimune Inc. | Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC | 11/24 | 11/24 | | |
|
|
|
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation |
|
|
| Recruiting | 1/2 | 230 | Europe, US, RoW | PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79 | PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer | 03/26 | 07/26 | | |
KEYNOTE-E28, NCT04429542: Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors |
|
|
| Recruiting | 1 | 292 | Canada, US | BCA101, Pembrolizumab | Bicara Therapeutics, Merck Sharp & Dohme LLC | Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck | 12/26 | 06/27 | | |
Drillon, Alexander |
NCT04982224: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer |
|
|
| Recruiting | 1/2 | 237 | US | REGN5093-M114, Cemiplimab | Regeneron Pharmaceuticals | Advanced NSCLC | 02/30 | 02/30 | | |
Robich, Michael |
| Recruiting | N/A | 6500 | Europe, Canada, US | AtriClip LAA Exclusion System | AtriCure, Inc., Population Health Research Institute | Ischemic Stroke, Systemic Embolism | 12/31 | 04/32 | | |
Millan, Rachel |
| Active, not recruiting | N/A | 464 | Europe, US | Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care | Nuvaira, Inc. | COPD | 09/24 | 09/28 | | |
Frasier, Brittany |
| Completed | 1/2 | 17 | US | Brentuximab Vedotin, Adcetris®, Placebo, Placebo for brentuximab vedotin | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Seagen Inc., PPD, Rho Federal Systems Division, Inc. | Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc | 04/23 | 04/23 | | |
Alexander, Mariam |
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 2 | 240 | Europe, US, RoW | CAB-AXL-ADC, BA3011, PD-1 inhibitor | BioAtla, Inc. | Non-Small-Cell Lung Cancer | 08/25 | 08/25 | | |
NCT05313009: Tarlox and Sotorasib in Patients With KRAS G12C Mutations |
|
|
| Terminated | 1/2 | 5 | US | Sotorasib and Tarloxotinib | Medical University of South Carolina, Rain Oncology Inc | Non-Small Cell Lung Cancer | 07/23 | 12/23 | | |
BA3021-001, NCT03504488: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) |
|
|
| Recruiting | 1/2 | 420 | Europe, US, RoW | CAB-ROR2-ADC, BA3021, PD-1 inhibitor | BioAtla, Inc. | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer | 12/25 | 12/25 | | |
NCT04982224: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer |
|
|
| Recruiting | 1/2 | 237 | US | REGN5093-M114, Cemiplimab | Regeneron Pharmaceuticals | Advanced NSCLC | 02/30 | 02/30 | | |
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 150 | Europe, US, RoW | MYTX-011 | Mythic Therapeutics | NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer | 12/25 | 12/27 | | |
Daher, Halim Bou |
NAVIGATE, NCT04365868: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis |
|
|
| Active, not recruiting | 2b | 357 | Europe, Canada, US, RoW | belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo | Galectin Therapeutics Inc. | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 12/24 | 12/24 | | |
Hayden, Gwen |
NCT04722887: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency |
|
|
| Recruiting | 1/2 | 16 | US | Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human), Prolastin®-C Liquid | Grifols Therapeutics LLC | Alpha1-Antitrypsin Deficiency | 03/25 | 03/25 | | |
Wright, Sharee |
NCT06007183: Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination |
|
|
| Recruiting | 3 | 800 | US | PXVX0317 vaccine booster, CHIKV VLP, Placebo booster | Bavarian Nordic | Chikungunya Virus Infection | 04/28 | 08/28 | | |
DEEPER REVEAL, NCT05358353: A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee |
|
|
| Recruiting | N/A | 130 | US | Bare Temporary Spur Stent System | ReFlow Medical, Inc. | Peripheral Arterial Disease, Critical Limb Ischemia | 10/24 | 10/24 | | |
Millare, Angela |
NCT05654922: Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant |
|
|
| Recruiting | 3 | 100 | US | ARINA-1, Standard of care only | Renovion, Inc. | Pre-Bronchiolitis Obliterans Syndrome | 01/25 | 06/25 | | |
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection |
|
|
| Recruiting | 2 | 60 | US | AP-PA02, Placebo | Armata Pharmaceuticals, Inc. | Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection | 07/24 | 08/24 | | |
| Active, not recruiting | 2 | 75 | US | Omadacycline Oral Tablet, Nuzyra, Placebo, placebo tablets | Paratek Pharmaceuticals Inc | Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection | 06/24 | 07/24 | | |
Shayla, Bergmann |
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD) |
|
|
| Recruiting | 3 | 71 | Europe, US, RoW | rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Von Willebrand Disease (VWD) | 03/25 | 03/25 | | |
Patillo, Kammie |
| Recruiting | 2/3 | 344 | Europe, Canada, US, RoW | Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets | Forma Therapeutics, Inc., Novo Nordisk A/S | Sickle Cell Disease | 12/25 | 12/26 | | |
NTMBresearch |
| Active, not recruiting | 2 | 75 | US | Omadacycline Oral Tablet, Nuzyra, Placebo, placebo tablets | Paratek Pharmaceuticals Inc | Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection | 06/24 | 07/24 | | |
Leitner, Alex |
| Recruiting | 2 | 45 | US | Pembrolizumab, KEYTRUDA®, MK-3475, Olaparib, AZD-2281, MK-7339, KU0059436, Cisplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-platinum, IMRT (intensity modulated radiation therapy) | UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC | Squamous Cell Carcinoma of Head and Neck | 10/25 | 10/26 | | |
| Recruiting | 1/2 | 284 | Europe, Japan, US, RoW | CLN-081, TAS6417; zipalertinib | Cullinan Therapeutics Inc. | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | 12/24 | 12/24 | | |
|
Schorr, Stephanie |
| Recruiting | N/A | 93 | US | AMDS | Artivion Inc., Syneos Health | Acute Aortic Dissection | 03/24 | 03/28 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 06/24 | 06/28 | | |
| Recruiting | N/A | 6500 | Europe, Canada, US | AtriClip LAA Exclusion System | AtriCure, Inc., Population Health Research Institute | Ischemic Stroke, Systemic Embolism | 12/31 | 04/32 | | |
McBride, Princeton |
| Active, not recruiting | 2 | 75 | US | Omadacycline Oral Tablet, Nuzyra, Placebo, placebo tablets | Paratek Pharmaceuticals Inc | Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection | 06/24 | 07/24 | | |
Avinger, Madison |
| Recruiting | 2 | 45 | US | Pembrolizumab, KEYTRUDA®, MK-3475, Olaparib, AZD-2281, MK-7339, KU0059436, Cisplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-platinum, IMRT (intensity modulated radiation therapy) | UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC | Squamous Cell Carcinoma of Head and Neck | 10/25 | 10/26 | | |
NCT05268614: Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 250 | US | Radiation therapy, Cisplatin | University of Florida, Naveris, Inc. | Oropharyngeal Squamous Cell Carcinoma | 06/29 | 06/32 | | |